Latest news, events, resources, and thought pieces from the Exchange's blog

ECHO Trial Results Show that Three Methods Do Not Increase Risk of HIV

On June 13, 2019, the results of the much-anticipated Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial were presented live at the SA AIDS 2019 conference in Durban, South...

Planning for Outcomes Tool Helps Estimate Impact of Changing Contraceptive Method Mix

Observational studies have raised concerns about the potential link between the use of progestin-only injectable contraception – specifically depot medroxyprogesterone acetate (DMPA) – and increased risk of HIV acquisition. In...

Contraceptive Innovation at Women Deliver – A Look at the Past, The Present, The Future

Next week, more than 8,000 researchers, policy makers, and advocates from 160+ countries will gather in Vancouver, British Columbia, to discuss the future of women: their health, their strength, and...

Product Registration: Pro Tips for Program Managers

New contraceptive products have the potential to help women and girls plan the families and lives they desire. Among the 214 million women in developing countries with an unmet need...

Male Contraception Initiative RFA is Now Open

MCI's 2019 FRA is open for submission. This funding will support research in reversible, non-hormonal male contraceptive discovery and development. MCI intends to fund up to five grants, ranging from...

One contraceptive for both men and women

YourChoice Therapeutics is attempting to revolutionize birth control options for women and men by developing options that are hormone-free, safe, easy to use, and effective. In men, the product disables...

More on the blog

Why Contraceptive Innovation?

Despite the availability of various contraceptive methods, more than 200 million women in developing countries want to avoid or delay pregnancy yet are not using an effective family planning method. For some of these women, access to contraception is limited. For others, currently available methods do not meet their needs or preferences or are unaffordable. Innovative solutions are needed in the areas of product development, registration, pricing, and introduction to address these barriers.

Join the exchange and become part of the solution!

Visit our resource library for additional information about the need for contraceptive innovation.


A one-stop shop for resources related to contraceptive research and development

The CTI Exchange offers resources about contraceptive research and development, including information about products currently in development, preclinical and clinical research, and opportunities for future investment. This easily searchable resource library also includes information about regulatory requirements, quality assurance standards, intellectual property, and product introduction strategies, as well as tools for advocacy.

View all resources

Featured Resources

Other key resources related to contraceptive research and development

Calliope, the Contraceptive Pipeline Database, includes information on potential contraceptive targets and leads, products in pre-clinical and clinical development, and a selection of novel and long-acting products with limited market availability.
CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, lists biological and chemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites, and use in marketed products.
Contraceptive Drug Interactions is a database that catalogues potential interactions between contraceptive drugs and drugs from other therapeutic classes. Changes in drug pharmacokinetics, effectiveness, and adverse effects are provided.


We want you to join the exchange!

The CTI Exchange looks to partners to help generate and share resources. Contact us with your ideas, materials, or questions, or sign up to receive more information. We also encourage you to provide your feedback